For decades, women drowning in menopausal hot flashes had two real choices: swallow a hormone or sweat through it. In May 2023, the FDA changed that equation. Veozah (fezolinetant) arrived as the first non-hormonal drug designed specifically to stop hot flashes at their neurological source. Two years on, with real-world data stacking up and a liver safety label in place, here is what every woman needs to know about Veozah for hot flashes before asking her doctor for a prescription.
How Veozah Works: The NK3 Receptor Mechanism
Veozah belongs to a drug class called neurokinin 3 (NK3) receptor antagonists. The science is surprisingly elegant. Before menopause, estrogen and a brain chemical called neurokinin B (NKB) exist in a careful balance inside the hypothalamus — the body’s thermostat. When estrogen drops during menopause, NKB runs unopposed. That imbalance makes the hypothalamus think the body is overheating, so it triggers a cascade of sweating, flushing, and chills that defines a hot flash.
Veozah blocks the NK3 receptor, the docking station NKB needs to deliver its signal. No signal, no false heat alarm. The drug was developed by Astellas Pharma, which acquired the compound from a Belgian biotech called Ogeda (originally Euroscreen) in 2017 for an undisclosed sum. The generic name is fezolinetant, and the standard dose is one 45-milligram tablet per day, taken at roughly the same time, with or without food. Patients typically see a reduction in hot flash frequency within one week, though maximum benefit takes about four weeks.
What makes this mechanism worth paying attention to is what it does not do. It does not touch estrogen receptors. It does not raise hormone levels. It works entirely through the brain’s thermoregulatory pathway. That separation from hormones is the entire point — and the entire reason it passed FDA scrutiny for women who cannot or will not take estrogen. The drug also differs from SSRIs like paroxetine, which doctors sometimes prescribe off-label for hot flashes. SSRIs work through serotonin pathways and carry their own side effect profile — weight gain, sexual dysfunction, emotional blunting. Veozah avoids those entirely because it does not touch serotonin at all.
What the SKYLIGHT Clinical Trials Found
The FDA based its approval on two phase III trials called SKYLIGHT 1 and SKYLIGHT 2, both published in The Lancet in March 2023. Each trial enrolled roughly 500 postmenopausal women averaging 54 years old who were experiencing moderate to severe hot flashes — defined as at least seven to eight moderate-to-severe episodes per day. That is a punishing baseline. A woman waking 7 or 8 times each night because of a temperature-control malfunction is not having a bad week. She is having a bad year.
The results were unambiguous. At week 12, women taking 45 milligrams of fezolinetant once daily reported a 60 to 65 percent reduction in hot flash frequency from baseline, compared with 42 to 48 percent in the placebo group. Severity scores dropped proportionally. The drug also worked for night sweats, which many women report as the most disruptive symptom because it destroys sleep architecture — not just the night itself but the next day’s cognitive function, mood, and energy.
After the initial 12-week placebo-controlled phase, all participants entered a 40-week open-label extension, bringing total trial duration to 52 weeks. The benefit held. No tachyphylaxis — meaning the drug did not lose effectiveness over time. A separate safety extension called SKYLIGHT 4 followed 1,830 women for the same duration and confirmed the liver signal that later shaped the FDA label warning added in September 2024.
The lead investigator of SKYLIGHT 1 was Dr. JoAnn Pinkerton, a professor of obstetrics and gynecology at the University of Virginia and a past executive director of the Menopause Society. She noted in published commentary that fezolinetant fills a gap for women who have contraindications to hormone therapy, such as a history of breast cancer or thromboembolic disease. Dr. Pinkerton also pointed out that the drug’s onset within one week is faster than most alternatives — a meaningful advantage for women in acute distress.
Veozah vs. Hormone Therapy: Key Differences
Hormone therapy remains the gold standard for hot flash relief, and it is remarkably effective — estrogen cuts hot flash frequency by 75 to 90 percent in most women. But hormone therapy carries baggage. The Women’s Health Initiative (WHI) trial, published in 2002, linked combined estrogen-progestin therapy to increased risks of breast cancer, stroke, and blood clots. Later reanalyses softened some of those conclusions — the risk varies dramatically by age at initiation, duration of use, and progestin type — but the damage to public perception was permanent. Many women and their doctors remain cautious.
Veozah sidesteps the entire hormone axis. It does not change estrogen, progesterone, or testosterone levels. It does not increase breast cancer risk, stroke risk, or clotting risk — at least not based on any data collected so far. The trade-off is that Veozah treats only vasomotor symptoms. It does not protect bone density, improve vaginal health, or reduce fracture risk the way estrogen does. A woman choosing Veozah over hormone therapy gains safety on the clotting and cancer fronts but loses the ancillary benefits that come with estrogen replacement — bone protection especially, since osteoporosis remains a leading cause of disability in older women.
There is also the liver concern, which hormone therapy does not carry. Every woman starting Veozah needs baseline liver function blood work, then repeat tests at months 1, 2, 3, 6, and 9. For some women, the blood draw schedule feels like a burden. For others, it is a fair price for a drug that does not increase breast cancer risk. The key question each woman must answer is personal: which risk profile fits her health history.
Side Effects and the Liver Safety Warning
The most common side effects of Veozah in clinical trials were mild. Abdominal pain, diarrhea, back pain, and insomnia each occurred in roughly 3 to 6 percent of patients, comparable to placebo rates. The drug also lists hot flash as a potential side effect — ironic, but rare in practice.
The serious concern is liver injury. In SKYLIGHT 4, a small number of women developed elevated liver enzymes at levels that triggered the FDA’s hepatotoxicity threshold. One woman met Hy’s Law criteria — a pattern of enzyme and bilirubin elevation that predicts a roughly 10 to 50 percent risk of fatal liver failure in historical drug data. She recovered after stopping the drug, but the signal was enough for the FDA to add a liver warning to the label in September 2024, four months after the initial approval. European regulators, who approved the drug as Veoza in December 2023, issued a matching warning.
Dr. Stephanie Faubion, director of the Mayo Clinic’s Women’s Health Clinic and medical director of the Menopause Society, told attendees at the 2024 North American Menopause Society meeting that the liver risk is real but rare — estimated at roughly 1 in 1,000 patients based on the trial data. She emphasized that the monitoring schedule is designed to catch problems early, when they are reversible. Nausea, fatigue, dark urine, and yellowing of the skin or eyes are the symptoms that should trigger an immediate call to a doctor and a stop to the medication.
Patients taking strong CYP1A2 inhibitors — a class that includes the antidepressant fluvoxamine (Luvox), the antibiotic ciprofloxacin (Cipro), and oral contraceptives — should not take Veozah because those drugs increase fezolinetant blood levels and raise the liver risk further. Caffeine is also a mild CYP1A2 inhibitor, so the label advises avoiding or limiting coffee, tea, chocolate, and energy drinks during treatment. This is a real practical consideration for women who rely on morning coffee — giving up caffeine while managing hot flashes is an added burden that patients and doctors need to discuss upfront.
Practical Takeaways: Cost, Dosage, and Who Should Consider It
Veozah is not cheap. Without insurance, a 30-day supply runs roughly $550 to $600 at most US pharmacies. Insurance coverage is improving but inconsistent — some plans place it on the highest tier, meaning copays of $100 or more per month. Astellas offers a savings card through VeozahDirect that can bring the cost down to $20 per month for commercially insured patients. For uninsured patients, options are limited unless they qualify for the Astellas Patient Assistance Program, which provides the drug free to those who meet income criteria.
- Dosage. One 45-milligram tablet daily. Do not crush or cut the tablet. Missed doses can be taken the same day as long as there are at least 12 hours before the next dose.
- Onset. Most women notice improvement within one week. Full effect by week four.
- Candidates. Women with moderate to severe hot flashes who cannot take hormone therapy due to breast cancer history, clotting disorders, migraine with aura, or personal preference.
- Non-candidates. Women with cirrhosis, severe kidney disease, pre-existing liver enzyme elevations above 2x the upper limit of normal, or those taking strong CYP1A2 inhibitors.
- Monitoring. Liver function blood tests before starting, then at months 1, 2, 3, 6, and 9. No breast exams or mammogram changes needed beyond routine screening.
The bottom line: Veozah is not a hormone therapy replacement. It is a targeted tool that solves one specific problem — hot flashes and night sweats — without touching the rest of the hormonal system. For the estimated 10 to 15 percent of menopausal women who cannot use estrogen, that is not a compromise. It is a solution that did not exist two years ago. The liver monitoring is inconvenient. The cost is high. But for a woman waking 8 times a night drenched in sweat, the math changes. Veozah works, it works fast, and it works without estrogen. That is worth discussing with a doctor today, not next year.